Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer.CAN-2409 data sends Candel Therapeutics stock up Copy link to section Patients on CAN-2409 showed a meaningful increase in survival in a Phase II study, as per the biotechnology company. No new safety concerns were discovered in the clinical trial either. Garrett Nichols – the chief medical officer of $CADL said in a press release today:“CA ...